Response from Ferring Pharmaceuticals

Moss‐made pharmaceuticals: from bench to bedside

Over the past two decades, the moss Physcomitrella patens has been developed from scratch to a model species in basic research and in biotechnology. A fully sequenced genome, outstanding possibilities for precise genome-engineering via homologous recombination (knockout moss), a certified GMP production in moss bioreactors, successful upscaling to 500 L wave reactors, excellent homogeneity of p...

Pharmaceuticals from natural products: current trends.

The use of products extracted from plants for medicinal purposes can be traced to the beginnings of civilization and up until the end of the nineteenth century natural products were the principal source of medicines. Since then their relative importance has oscillated according to the strategies of large pharmaceutical companies. Now that these strategies are changing, there are new opportuniti...

Smart Pharmaceuticals

Patents as a Spur to Subsequent Innovation? Evidence from Pharmaceuticals

This paper examines how an incumbent’s patent protection acts as an implicit subsidy toward non-infringing substitutes. I analyze whether classes of pharmaceuticals whose first entrant has a longer period of market exclusivity (time between approval and generic entry) see more subsequent entry. Instrumenting for exclusivity using plausibly exogenous delays in the development process, I find tha...

Removal of pharmaceuticals from industrial wastewaters by microalgae culture